Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Tan

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Molecular Cancer Therapeutics|October 8, 2009
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugatesBing Zheng, Reina N Fuji, Kristi Elkins, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2020
Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in UgandaEmmanuel Ndashimye, Mariano Avino, Abayomi S Olabode, et al.
Nature|December 22, 2006
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesisJohn Ridgway, Gu Zhang, Yan Wu, et al.
Cancer Research|May 1, 2002
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugateSarajane Ross, Susan D Spencer, Ilona Holcomb, et al.
Nature|December 25, 2015
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell functionElaine E Storm, Steffen Durinck, Felipe de Sousa e Melo, et al.
Blood|March 22, 2007
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphomaAndrew G Polson, Shang-Fan Yu, Kristi Elkins, et al.
Neuron|December 22, 2015
Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic AntibodiesY Joy Yu Zuchero, Xiaocheng Chen, Nga Bien-Ly, et al.
Science Translational Medicine|November 8, 2014
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primatesY Joy Yu, Jasvinder K Atwal, Yin Zhang, et al.
Molecular Cancer Therapeutics|September 16, 2008
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptakeYonglei Shang, Yifan Mao, Jennifer Batson, et al.
Cell|April 8, 2010
PlGF blockade does not inhibit angiogenesis during primary tumor growthCarlos Bais, Xiumin Wu, Jenny Yao, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Molecular Cancer Therapeutics|October 8, 2009
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugatesBing Zheng, Reina N Fuji, Kristi Elkins, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2020
Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in UgandaEmmanuel Ndashimye, Mariano Avino, Abayomi S Olabode, et al.
Nature|December 22, 2006
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesisJohn Ridgway, Gu Zhang, Yan Wu, et al.
Cancer Research|May 1, 2002
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugateSarajane Ross, Susan D Spencer, Ilona Holcomb, et al.
Nature|December 25, 2015
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell functionElaine E Storm, Steffen Durinck, Felipe de Sousa e Melo, et al.
Blood|March 22, 2007
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphomaAndrew G Polson, Shang-Fan Yu, Kristi Elkins, et al.
Neuron|December 22, 2015
Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic AntibodiesY Joy Yu Zuchero, Xiaocheng Chen, Nga Bien-Ly, et al.
Science Translational Medicine|November 8, 2014
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primatesY Joy Yu, Jasvinder K Atwal, Yin Zhang, et al.
Molecular Cancer Therapeutics|September 16, 2008
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptakeYonglei Shang, Yifan Mao, Jennifer Batson, et al.
Cell|April 8, 2010
PlGF blockade does not inhibit angiogenesis during primary tumor growthCarlos Bais, Xiumin Wu, Jenny Yao, et al.
Pageof 3